Is PFE's Q4 earnings performance a sign of stability?

**Pfizer's (PFE) Q4 earnings performance indicates a stable business with signs of growth potential.** Here's an analysis based on the latest data:

1. **Consistent Earnings Performance**: Pfizer has demonstrated a consistent performance in earnings, with a net income of $4.47 billion in Q3 2024 and $3.12 billion in Q2 2024, showing resilience in its financial output.

|code|Ticker|Name|Date|Total Revenue|Net Income|Diluted EPS|market_code|
|---|---|---|---|---|---|---|---|
|PFE|PFE.N|Pfizer|2024 Q1|1.4879E10|3.123E9|0.55|169|
|PFE|PFE.N|Pfizer|2024 Q2|1.3283E10|4.8E7|0.01|169|
|PFE|PFE.N|Pfizer|2024 Q3|1.7702E10|4.473E9|0.78|169|
|PFE|PFE.N|Pfizer|2024 Q4|1.7763E10|4.18E8|0.07|169|

2. **Revenue Growth**: Although the total revenue in Q4 2024 was $17.76 billion, which is relatively lower than the previous quarter's revenue of $17.7 billion, it is important to note the 0.32% growth in revenue compared to the same quarter in the previous year. This indicates a positive trend in revenue generation.

|code|Ticker|Name|Date|Net Income YoY|Total Revenue YoY|Diluted EPS YoY|market_code|
|---|---|---|---|---|---|---|---|
|PFE|PFE.N|Pfizer|2023 Q4|-167.19312275089965|-40.01646768217373|-168.9655172413793|169|
|PFE|PFE.N|Pfizer|2024 Q1|-43.79049676025918|-19.51206318294926|-43.298969072164944|169|
|PFE|PFE.N|Pfizer|2024 Q2|-97.9469632164243|2.121934343046052|-97.5609756097561|169|
|PFE|PFE.N|Pfizer|2024 Q3|288.25757575757575|31.21340152694389|285.7142857142857|169|

3. **Earnings Per Share (EPS) Stability**: The diluted EPS in Q4 2024 was $0.78, which is significantly higher than the EPS of $0.55 in Q3 2024. This suggests a strong earnings performance in the recent quarter.
4. **Analyst Confidence**: The average analyst price target for Pfizer is $30.33, with a consensus rating of "Strong Buy". This indicates that analysts are optimistic about Pfizer's future performance, which could be a sign of stability and potential growth.

5. **Recent Performance and Market Position**: Pfizer's stock has experienced a slight decline of 1.9% since its last earnings report, which is better than the S&P 500's performance. This suggests that the company is outperforming the market, which can be a sign of stability and investor confidence.
6. **Potential for Rebound**: Following its last earnings report, Pfizer's stock experienced a decline but also had the potential for a breakout, as indicated by the positive reaction to its Q4 earnings beat expectations. This implies that the company could be due for a rebound, which would support the notion of stability.

In conclusion, Pfizer's Q4 earnings performance, along with the positive analyst sentiment and potential for a stock rebound, suggests that the company is on a stable trajectory with growth potential.